Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities
AK Conlin, AD Seidman - Clinical breast cancer, 2008 - Elsevier
As reflected in its varied clinical behavior, appearances under the light microscope, and
differential patterns of gene expression, metastatic breast cancer (MBC) is a heterogeneous
disease. Systemic treatment decisions are guided by specific tumor characteristics and
individual patient factors. For patients with hormone receptor (HR)–negative MBC and for
those whose HR–positive disease has become refractory to hormonal therapies, cytotoxic
chemotherapy has been the mainstay of systemic treatment. For hormone-insensitive, HER2 …
differential patterns of gene expression, metastatic breast cancer (MBC) is a heterogeneous
disease. Systemic treatment decisions are guided by specific tumor characteristics and
individual patient factors. For patients with hormone receptor (HR)–negative MBC and for
those whose HR–positive disease has become refractory to hormonal therapies, cytotoxic
chemotherapy has been the mainstay of systemic treatment. For hormone-insensitive, HER2 …